IVGN Invitrogen (MM)

Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of its Invivofectamine� delivery reagent which enables short interference ribonucleic acid (siRNA) experiments in vivo. The study of RNA interference (RNAi) has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. Using proprietary technology, the Invivofectamine� delivery reagent allows researchers to directly study the effects of siRNA inside a living organism for a variety of applications, including the drug discovery process. �The Invivofectamine� reagent is a major breakthrough for the development of RNAi applications in animals that could lead to the rapid discovery of new therapeutic solutions for diseases such as cancer and metabolic diseases,� said Charles Piazza, Vice President and General Manager of Invitrogen�s Molecular Biology. �Invivofectamine� reagent gives customers the ability to perform in vivo RNAi experiments that have so far been difficult to perform due to the lack of an effective and easy-to-use delivery reagent.� As opposed to current offerings on the market, Invivofectamine� delivery reagent can be injected in small volumes and without high pressure, minimizing the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo. For more information, visit www.invitrogen.com/invivornai. About Invitrogen Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com. Safe Harbor Statement Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward looking statements include, but are not limited to; 1) the characteristics of Invivofectamine� delivery reagent listed above will enable researchers to more effectively optimize their siRNA experiments in vivo. Potential risks and uncertainties include, but are not limited to; a) Invivofectamine� delivery reagent may or may not allow researchers to study the effects of siRNA in vivo or inside a living organism, nor lead to rapid discovery of therapeutic solutions; b) Invivofectamine� may or may not provide extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown; and the risks that the market will not accept the companies� products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.